Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.
In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $445.00. The company’s shares ...
BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having surveyed 35 key opinion leaders who treat a total of ...
When Serbia’s broadcast regulator REM awarded a cable licence to Tanjug TV in 2021, the regulator’s head failed to reveal she ...
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
As the new US administration ramps up plans to deport illegal immigrants, Western Balkan countries likely to receive some of them are mulling how to deal with convicted criminals arriving with ...
Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...
OrgChart JS is a simple, flexible and highly customizable organization chart plugin for presenting the structure of your organization and the relationships in an elegant way.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback